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Abstract
Hepatocellular carcinoma (HCC) is the most common 
primary liver malignant neoplasia. HCC is characterized 
by a poor prognosis. The need to find new molecular 
markers for its diagnosis and prognosis has led to a 
progressive increase in the number of scientific studies 
on this topic. MicroRNAs (miRNAs) are small non-
coding RNA that play a role in almost all main cellular 
pathways. miRNAs are involved in the regulation 
of expression of the major tumor-related genes 
in carcinogenesis, acting as oncogenes or tumor 
suppressor genes. The aim of this review was to identify 
papers published in 2017 investigating the role of 
miRNAs in HCC tumorigenesis. miRNAs were classified 
according to their role in the main molecular pathways 
involved in HCC tumorigenesis: (1) mTOR; (2) Wnt; 
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(3) JAK/STAT; (4) apoptosis; and (5) MAPK. The role 
of miRNAs in prognosis/response prediction was taken 
into consideration. Bearing in mind that the analysis 
of miRNAs in serum and other body fluids would be 
crucial for clinical management, the role of circulating 
miRNAs in HCC patients was also investigated. The most 
represented miRNA-regulated pathway in HCC is mTOR, 
but apoptosis, Wnt, JAK/STAT or MAPK pathways are 
also influenced by miRNA expression levels. These 
miRNAs could thus be used in clinical practice as 
diagnostic, prognostic or therapeutic targets for HCC 
treatment.
Key words: MicroRNA; Molecular pathway; mTOR; 
Prognosis; Hepatocellular carcinoma; Review
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Hepatocellular carcinoma (HCC) is the most 
common primary liver neoplasia and is characterized by 
a poor prognosis. MicroRNAs (miRNAs) are involved in 
the regulation of expression of the major tumor-related 
pathways in carcinogenesis and may act as oncogenes 
or tumor suppressor genes. mTOR is the most 
represented miRNA-regulated pathway in HCC. miRNAs 
found to be deregulated in HCC could be used in 
clinical practice as diagnostic, prognostic or therapeutic 
targets.
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INTRODUCTION
Hepatocellular carcinoma (HCC), the most common 
primary liver malignant neoplasia, is a very diffuse mali­
gnancy, with variable incidence according to geography, 
and represents the fifth cause of cancer-related death 
worldwide[1,2]. Generally, HCC is characterized by a 
poor prognosis, mainly due to the limited treatment 
choices[3]: prognosis after surgery ­ including liver 
transplantation ­ depends on the tumor stage, the asso­
ciation with cirrhosis and on liver function[4]. Histology 
can be of little help in predicting the response to 
surgery, since the classic well­established histological 
features of HCC are seldom evaluable on liver needle 
biopsy: microvascular invasion (MVI) is rarely seen 
on biopsy, and tumor grade and architecture are too 
heterogeneous in HCC to be assessed on the basis of 
small sampling. Up to now, the most reliable prognostic 
markers after surgery are clinical and surgical, e.g., the 
complete resection of the lesion, liver function tests, 
and alpha­fetoprotein[5]. For liver transplantation, the 
inclusion within the Milan criteria remains a cornerstone 
for the good outcome of the recipients[6].
As for the systemic therapy for HCC, no serious 
options have been available until 2007, when the 
neoangiogenesis agent Sorafenib was introduced. 
Sorafenib gave one more chance to those patients 
with high­stage and MVI­positive HCC, not suitable for 
surgery[7,8]. Again, no predictive tests are available to 
assess which patients will benefit most from Sorafenib 
therapy.
The need to find new tissue and/or serum markers 
for HCC diagnosis and prognosis progressively increased 
the number of studies on the molecular mechanism 
behind liver carcinogenesis. The issue, however, still 
remains tangled, due to the high heterogeneity of HCC 
(not only in phenotype), and to the complex multistep 
carcinogenesis occurring differently in cirrhotic and non­
cirrhotic livers[2].
MicroRNAs (miRNAs) are small non­coding RNA 
(20­25 nucleotides) that play a role in almost all main 
cellular pathways[9]. miRNAs contribute to a variety of 
physiological and pathological events, including several 
types of tumors[10­15]. Thus, miRNAs are involved in the 
regulation of expression of the major tumor­related 
genes in carcinogenesis, acting as oncogenes or tumor 
suppressor genes[16].
The aim of this review was to identify papers 
published in the last 12 mo (from January 2017 to 
December 2017), investigating the possible role of 
miRNAs in HCC tumorigenesis. miRNAs were classified 
according to their role in the main molecular pathways 
involved in HCC: (1) mTOR; (2) Wnt; (3) JAK/STAT; (4) 
apoptosis; and (5) MAPK. Moreover, the possible role 
of miRNAs in prognosis/response prediction and the 
level of circulating miRNAs in HCC patients were also 
investigated.
mIRNAs IN HCC mOLECULAR 
PATHWAYs
mTOR pathway
mTOR (mammalian target of rapamycin) is a well con­
served serine­threonine kinase that plays a fundamental 
role in the signaling network that controls growth and cell 
metabolism. mTOR is the physical target of rapamycin. 
mTOR exists in two different multi­protein complexes: 
mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2). mTORC1 is composed of five components: 
mTOR, Raptor, PRAS40, GβL, and DEPTOR[17]. mTORC1 
is directly inhibited by rapamycin but, at the same time, 
it is modulated by genotoxic stress, growth factors, 
oxygen and energy status, resulting in modulation of 
cell growth and proliferation[18]. These inputs indirectly 
regulate mTORC1 by controlling the activation status of 
TSC1­TSC2. For example, growth factors block TSC1­
TSC2 and mTORC1 is consequently activated. On the 
contrary, energy deficit, genotoxic stress or oxygen 
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deprivation are positive signals on TSC1­TSC2, which 
inhibit mTORC1. Activated mTORC1 promotes protein 
synthesis and lipid biogenesis, it controls mitochondrial 
metabolism and biogenesis; it also inhibits catabolism by 
blocking autophagy and it inhibits growth factor signaling 
by activating negative feedback loops that block the PI3K 
pathway[18­20].
The second complex, mTORC2, is composed of six 
components: mTOR, Rictor, GβL, Sin1, PRR5/Protor-1, and 
DEPTOR. mTORC2 regulates cellular survival, cytoskeletal 
organization and metabolism. Compared to mTORC1, 
the mechanisms of mTORC2 are less understood: It is 
insensitive to acute treatment with rapamycin, but it was 
reported that a long­term treatment with rapamycin 
reduces mTORC2 signaling, suppressing the assembly 
of the complex[19,21]. This complex is activated by growth 
factors with a PI3K­dependent mechanism and the work 
of Zinzalla et al[22] suggested a possible role of ribosomes 
for mTORC2 complex activation[20,22].
Due to its key role in regulating cell growth, survival 
and metabolism, the mTOR pathway is aberrantly 
activated in many diseases, including cancer, cardio­
vascular disease and diabetes[20]. In up to 50% of HCC 
cases, an aberrant activation of mTOR was reported, 
mainly downstream of the insulin growth factor (IGF) or 
epidermal growth factor (EGF) signaling cascades[23].
Many studies showed tumor suppressor miRNAs, the 
down­regulation of which lead to the mTOR pathway 
activation in HCC cells. 
miR-758-3p: Jiang et al[24] showed that the restoration 
of miR­758­3p in HCC cell line could suppress cell 
proliferation, migration, and invasion. miR­758­3p 
markedly down­regulates the expression of MDM2 and 
mTOR and, at the same time, the expression of p53, 
AKT and PRAS40 resulted up­regulated. mTOR can 
be regulated by its upstream effector AKT, which can 
suppress PRAS40 so as to eliminate the inhibition it 
exerts on mTORC1[24]. 
miR-142: Yu et al[25] demonstrated that miR­142 
expression was reduced in 50 tumor tissues in 
comparison to correspondent normal tissues and in 
two HCC cell lines compared to human normal liver cell 
line. This lower expression was linked to poor clinical 
parameters like high TNM stage and distant metastasis. 
miR-142 was identified to directly target the transforming 
growth factor β (TGF­β), which controls cell vitality, 
proliferation, epithelial­mesenchymal transition (EMT) 
and neo­angiogenesis. mTOR is one of the effector 
pathways of TGF­β signaling. These findings imply 
that miR­142 is a tumour suppressor gene in HCC and 
that it increases the TGF­β­induced development of 
hepatocellular carcinoma[25].
miR-199b-5p: In 100 pairs of HCC patients’ tumor 
tissues and adjacent liver tissues a significant down­
regulation of miR­199b­5p was observed and associated 
to poor clinical outcome. N­cadherin was the demon­
strated target of miR­199b­5p and it promoted EMT in 
HCC cells. The restoration of miR­199b­5p suppressed 
cell migration, invasion and metastasis in xenograft 
tumors. It was demonstrated that the miR­199b­5p 
overexpression lead to suppression of TGF­β1­induced 
Akt phosphorylation. Moreover, inhibition of the PI3K/Akt 
signaling pathway blocked TGF­β1­induced N­cadherin 
overexpression in HCC cells. The inhibitory effects on 
EMT and on the TGF­β1 signaling pathway support the 
potential use of miR­199b­5p as a promising strategy to 
treat HCC[26].
miR-187, miR-497, miR-99a, miR-592: IGF­
1R activation, through the PI3K/Akt/mTOR axis, is 
responsible for cell proliferation, migration and invasion in 
HCC[27]. IGF­1R is a target of miR­187, miR­497, miR­99a 
and miR­592[28­30]. miR­187 was found downregulated in 
HCC tissues and cell lines: as reported by Han et al[29], 
the restoration of miR­187 leads to a significant arrest 
of HCC growth. miR-497 and miR-99a target the 3′-UTR 
of both IGF­1R and mTOR and were shown to be down­
regulated in HCC human tissues and cell lines: the co­
transfection with both miRNAs slowed cell proliferation 
and the tumor growth in HCC cell lines and in xenograft 
models[28]. Wang and colleagues demonstrated that 
miR-592 was significantly downregulated in HCC tissues 
and cell lines and that its low expression was associated 
with lymph node metastases[30]. These results indicated 
that miR­187, miR­497, miR­99a, miR­592 could be 
investigated as potential therapeutic targets for HCC in 
the future.
miR-296-5p: The low expression of miR­296­5p is 
directly linked to the activation of the mTOR pathway in 
HCC growth. Gain­of­function experiments demonstrated 
that miR­296­5p inhibited HCC cell proliferation, 
migration and invasion in vitro, by targeting AKT2. These 
findings indicated that the miR-296-5p/AKT2 axis plays 
important roles in HCC carcinogenesis and progression, 
and that miR-296-5p/AKT2 could be considered a 
potential target for HCC therapy[31].
miR-139-5p: PDK1/AKT/mTOR axis activation could 
lead to hepatocellular carcinoma cell proliferation. PDK1 
is a known target of miR­139­5p, found down­regulated 
in HCC tissues and cell lines. Mo et al[32] also observed 
that miR139-5p/PDK1 expression was regulated by 
long­coding RNA XIST, which was found over­expressed 
in HCC.
miR-15b-5p: Opa interacting protein 5 (OIP5) was 
found up­regulated in HCC, inducing tumor growth and 
metastasis in vitro and in vivo. OIP5 induces mTORC1 
and GSK­3β/β­catenin signaling activation, through AKT. 
miR­15b­5p was found down­regulated in HCC cells and 
OIP5 was found to be its direct target. These findings 
suggest that the restoration of miR­15b­5p could inhibit 
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invasion of HCC cells by targeting PTEN, the reduction 
of which activates the PI3K/Akt pathway[39]. Another 
miRNA was found to be over­expressed in HCC and 
plays an oncogenic role in HCC by targeting PTEN: miR­
155­5p promotes cell growth, migration and invasion, 
but inhibits apoptosis in vitro and promoted HCC 
progression in vivo[40]. PTEN is a known target also of 
miR­25, which is over­expressed in HCC cell lines and in 
liver cancer stem cells (LCSCs)[41].
Wnt signaling pathway
β­catenin phosphorylation and degradation and its 
regulation by Wnt are the essence of the Wnt pathway. 
Signaling by the Wnt family proteins is one of the 
fundamental mechanisms that induce cell proliferation, 
cell polarity and cell fate during development and tissue 
homeostasis (Logan and Nusse, 2004). Canonical 
Wnt signaling functions by regulating the amount of 
β­catenin. In the absence of Wnt, cytoplasmic β­catenin 
protein is degraded by the Axin complex. This non­
stop degradation prevents β­catenin from reaching 
the nucleus, and Wnt target genes are thereby 
repressed[42­44]. Inhibitors of Wnt signaling might be 
effective in HCC, where mutations in the Wnt pathway 
components are quite common. In the HepG2 cell line, 
knockdown of β­catenin, mediated by RNA interference, 
decreased proliferation and growth in vitro[45,46] (Figure 1).
miRNA-10a, miR-30e, miR-215, miR-125b and 
miR-148a: Ashmawy and colleagues observed that 
11 miRNAs (miR­10a, miR­106b, miR­99a, miR­148a, 
miR­125b, miR­30e, miR­199a, miR­199a3p, miR­24, 
miR­122 and miR­215) were down­regulated in HCC 
patients. Five of these miRNAs (miRNA­10a, miR­
30e, miR­215, miR­125b and miR­148a) were also 
associated with the expression of genes involved in the 
Wnt/β­catenin pathway, such as β­catenin, APC and 
c­myc[47].
miR-155 and miR-183: In the same study, the 
authors detected that miR­155 and miR­183 were up­
regulated in HCC patients if compared to controls and 
that miR­155 was correlated with liver cirrhosis[47].
miR-18a: Other than miR­155 and miR­183, other 
miRNAs involved in the Wnt/b-catenin pathway were 
observed up­regulated in HCC. Liu et al[48] identified 
that miR­18a expression was upregulated in human 
HCC if compared to the adjacent non­tumoral liver 
tissue. This up­regulation promotes the proliferation and 
migration of HCC cell lines by inhibiting KLF4, a factor 
that negatively regulates β­catenin expression. This 
data led the authors to hypothesize that miR­18 could 
be a therapeutic target for HCC treatment[48].
miR-195: Yan and colleagues showed a potential 
application of miR­195 in the cancer therapy of HCC. 
They observed that miR­195 was markedly down­
OIP5­mediated oncogenic signaling in HCC[33].
miR-345: Yu and colleagues found that the expression 
of miR-345 was significantly down-regulated in 65 HCC 
cases, and matching tumor­adjacent tissues, and in HCC 
cell lines. They also reported a clinical correlation between 
the low expression of miR­345 and venous infiltration, 
multiple lymph node metastases, and advanced TNM 
stage. The restoration of miR­345 inhibited migration and 
invasion ability of HCC cells. It was demonstrated that 
interferon regulatory factor 1 (IRF1) was a direct target 
of miR­345 and that IRF­1 mediated the oncogenic 
effects triggering mTOR/STAT3/AKT signaling[34].
miR-223: Dong and colleagues showed that miR­223 
was able to suppress cell growth and to promote 
apoptosis in HCC cell lines (HepG2 and Bel­7402). Ras­
related protein Rab­1(Rab1) is specifically regulated 
by miR­223. These data suggested that, in HCC cells, 
the anti­tumor effects due to miR­223 restoration 
may be due to the inactivation of the mTOR pathway, 
caused by the suppression of Rab1 when miR­223 is 
over­expressed. According to these results, miR­223 
may be a potential therapeutic target for treating HCC, 
mediating mTOR signaling silencing[35].
Other studies showed oncogenic miRNAs, the 
upregulation of which leads to the mTOR pathway 
activation in HCC cells. 
miR-33a: The levels of miR­33a were observed as 
significantly higher in HCC tissues than in adjacent 
non­tumor tissues. This elevated expression of miR­
33a correlated with adverse clinical features and poor 
prognosis. It was demonstrated that miR­33a could 
promote cell growth by modulating the proliferation and 
apoptosis of HCC cells. Its direct target is PPARα, one of 
the targets of mTORC1[36].
miR-302d: Chen and colleagues demonstrated that 
the overexpression of miR­302d promoted cell growth 
and migration and suppressed apoptosis in HCC cell 
lines and that it promotes xenograft tumor growth in 
vivo. These mechanisms were found to be mediated by 
TGFbR2­signaling, a target of miR­302d[37].
miR-23b: miR­23b was found to be significantly up­
regulated in tumor tissues of HCC patients. It was 
demonstrated that this miRNA regulated ST7L, a 
suppressor of the AKT/GSK3β/β­catenin pathway in 
HCC cells. MiR­23b thus acts as an oncomir in HCC, 
stimulating proliferation and metastasis through the 
mTOR and β­catenin signaling cascades[38].
miR-181a, miR-155-5p, miR-25: miR­181a was 
found to be up­regulated in HCC tissues compared to 
adjacent tissues; moreover, its levels were dramatically 
higher in metastatic HCC tissues than in non­metastatic 
HCC tissues. miR­181a regulates the proliferation and 
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regulated both in HCC cell lines and in 36 HCCs 
compared to adjacent non­tumoral liver tissues. The 
expression of miR­195 was inversely correlated with 
AEG­1 expression, which was demonstrated to be a 
target of miR­195. Overexpression of AEG­1 activates 
the PI3K/Akt, nuclear factor-κB, and Wnt/β­catenin 
signaling pathways stimulating proliferation, metastasis, 
angiogenesis and chemoresistance[49]. An analysis 
performed using miR­195 mimics showed how miR­195 
inhibited liver cancer cell growth and induced apoptosis 
in HCC cell lines. The overexpression of miR­195 also 
decreased tumor growth of hepatoma xenografts in 
nude mice[50].
miR-320a: miR­320a was observed to be down­
regulated in HCC tissues if compared to paired adjacent 
non­tumoral liver tissues. In samples with miR­320a 
inhibition, an up­regulation of the expression levels of 
β­catenin, c­myc, cyclin D1 and DKK­1 was observed. 
According to this data miR­320a may be considered as 
a tumor­suppressive microRNA in human HCC, through 
the down­regulation of the β­catenin pathway[51]. 
miR320a was observed to be down­regulated also in 
a cohort of 50 HCC tissues by Xie and colleagues. The 
authors also identified c-Myc as a direct target of miR-
320a and observed that inducing upregulation of miR­
320a in HCC leads to inhibition of HCC cell proliferation 
and invasion capability through c­Myc silencing. 
These data support the role of miR320a as a tumor­
suppressive microRNA in HCC and provide evidence 
that miR­320a may be used as a potential target for 
HCC treatment[52].
miR-98-5p: Another miRNA observed to be down­
regulated in HCC tissues is miR­98­5p. Down­regulation 
of miR­98­5p correlates with tumor size, lymph node 
metastasis, and clinical stage. In addition, HCC patients 
with low expression of miR­98­5p had a shorter survival 
time compared to those with high miR­98­5p levels. 
miR­98­5p down­regulation in HCC has been associated 
with up­regulation of Insulin­like growth factor 2 mRNA­
binding protein 1 (IGF2BP1) in HCC, which induces cell 
proliferation while inhibiting cell apoptosis[53].
miR-15b-5p: As reported above (see mTOR pathway 
paragraph), miR-15b-5p is involved in AKT/mTOR 
pathway. However, its expression also inhibits GSK­3β/
β­catenin signaling in HCC[33].
miR-1247-5p: miR­1247­5p levels are down­regulated 
in patients with HCC and in HCC cell lines. This 
































Figure 1  Wnt signaling. MicroRNAs deregulated in hepatocellular carcinoma and involved in Wnt signaling pathway. 
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of miR­1247­5p gene. Also, the overexpression of 
miR­1247­5p inhibits the invasion and proliferation 
of HepG2 cells, induces cell apoptosis in vitro, and 
suppresses the growth of transplanted tumors in vivo. 
Wnt3 is a target of miR­1247­5p and overexpression 
of miR­1247­5p significantly down­regulated its 
expression. The evidence that the expression of miR­
1247­5p can be regulated by methylation indicates that 
miR­1247­5p may be a potential therapeutic target for 
HCC[54].
JAK-STAT pathway 
The JAK/STAT pathway regulates development and it is 
involved in stem cell maintenance, hematopoiesis and 
inflammatory response. Active JAKs recruit STAT (signal 
transducers and activators of transcription) proteins 
that form dimers that translocate to the nucleus when 
phosphorylated. These dimers modulate transcription 
of genes involved in differentiation, proliferation and 
apoptosis. The JAK/STAT pathway is regulated at 
multiple levels. Many cancers and neoplastic cells 
employ several strategies to activate the JAK/STAT 
pathway (e.g., activating mutations in STATs or reduced 
expression of negative regulators[55­57]) (Figure 2).
miR-214-3p: miR­214­3p is expressed at low levels 
in HCC[58]. PIM-1 is an oncogene encoding for a serine/
threonine kinase protein involved in several human 
cancers. PIM­1 transcription is initiated by STAT proteins 
and plays a key role in signal transduction, contributing 
to both cell proliferation and survival, and thus providing 
an advantage in tumorigenesis[59]. PIM­1 is a miR­214­
3p target and PIM­1 expression is enhanced in HCC[58].
miR-30e: miR­30e is down­regulated in the majority 
of HCC tissues. Restoration of its expression down­
regulates JAK1 expression levels. Silencing JAK1 inhibits 
migration, proliferation and invasion of HCC cells. For 
this reason, miR­30e might be a prognostic marker of 
HCC and a putative therapeutic target[60].
miR-340: JAK-1 was also identified as a direct target of 
miR-340. miR-340 was found to be significantly down-
regulated in HCC tissues and cell lines and, in vitro, its 
overexpression inhibited migration, cell proliferation and 
invasion[61].
miR-140-5p and miR-200: miR­140­5p and miR­200 
were down­regulated in HCC and predicted to target 
Pin1[62]. Pin­1 is an independent factor for poor prognosis 
in HCC, it is overexpressed in ~70% of human HCCs[63], 
and it is correlated with larger tumor size, higher 
incidence of MVI and poor prognosis in HCC[64]. The 
over­expression of miR­140­5p inhibits human HCC cell 
growth, colony formation and migration[62].
miR-638: miR­638 expression in HCC tissues is down­
regulated if compared to the paired non­tumoral 
tissues. Low expression of miR­638 was linked to 
venous infiltration and TNM stage. Moreover, low levels 
of miR­638 are associated with a lower E­cadherin and 
vimentin expression if compared to cells showing high 
miR­638 levels. miR­638 down­regulation increases 
SOX2 expression, a gene overexpressed in HCC and 
involved in oncogenesis and in the progression of 
various cancers[65,66]. Moreover, SOX2 expression is 
associated with overall poor survival in HCC patients 
and it promotes cancer cell invasion[67]. These data lead 
to considering miR­638­SOX2 as a putative target for 
repressing the development and metastasis of HCC[68].
Apoptosis
Apoptosis occurs normally during development to 
maintain cell populations in tissues and as a defense 
mechanism in immune reactions or when cells are 
damaged[69,70]. TP53 was the first tumor suppressor gene 
to be linked to apoptosis and it is well established that 
TP53 mutations occur in the vast majority of human 
cancers[71]. In fact, if on one hand wild type p53 promotes 
apoptosis, cell­cycle arrest and senescence, the loss of 
p53 function increases viability, chromosomal instability 
and cellular lifespan. Disruption of the apoptotic pathway 
correlates with the progression of several tumors[72].
miR-30a: Anoikis is a form of cell death due to loss 
of contact of the cells with the extracellular matrix. 
Low levels of miR­30a were observed in several HCC 
cell lines (Hep3B, HepG2, SMMC­7721, MHCC97­L, 
MHCC97­H and HCCLM3) and in HCC tumor tissue 
compared to adjacent non­neoplastic tissue. miR­
30a silencing is accompanied by an increase in the 
expression of Beclin 1 and Atg5 proteins and by a 
decreased number of cells undergoing anoikis[73].
miR-365: miR-365 expression was significantly lower 
in HCC cells (SMC7721, HepG2, Bel7404 and Bel7402) 
compared to a normal hepatocellular cell line (LO2). 
Inducing up-regulation of miR-365 leads to a significant 
decrease in cellular activity and to the inhibition of tumor 
growth. It has also been observed that in cells with an 
up­regulation of miR­365, the expression of Bax, cyto C 
and cleaved caspase 3, which is downstream of Bcl­2, 
were also markedly up­regulated[74].
miR-526a: miR­526a is down­regulated in HCC tissues. 
In vitro, the introduction of miR­526a into HCC cell lines 
significantly decreased HCC proliferation, migration and 
invasion, via p21 inactivation[75].
miR-377: miR­377 was down­regulated in HCC tumors 
if compared to the adjacent non­neoplastic tissue. In 
vitro experiments with HCC cell lines demonstrated that 
a gain of miR­377 function inhibited colony formation, 
suggesting that miR­377 plays a key role as a tumor 
suppressor in HCC. In cells with high levels of miR­377 
the apoptotic rate was significantly higher than in the 
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controls. Bcl­xL is an anti­apoptotic protein and it is 
overexpressed in about 33% of HCC[76], conferring 
resistance to apoptosis. The higher level of apoptotic 
rate observed in cell lines with miR­377 over­expression 
was associated with a concomitant down­regulation of 
Bcl­xL mRNA levels, suggesting that Bcl­xL is a target of 
miR­377[77].
miR-199a-5p: miR­199a­5p was down­regulated in 
HCC tissues compared to pair­matched non­neoplastic 
hepatic tissues[78], and the same was the case for let­
7c expression[79]. miR­199a­5p down­regulation was 
correlated with tumor size and invasion. Moreover, 
the low expression of miR­199a­5p and let­7c was 
associated with higher metastatic capability in HCC cell 
lines. MAP4K3 is a pro­apoptotic kinase that activates 
the Intrinsic Apoptosis Pathway[80]. MAP4K3 gene was 
predicted as a possible target of miR­199a­5p and let­
7c and the up­regulation of both miRNAs leads to a 
significant decrease in MAP4K3 protein level, resulting 
also in a decrease in HCC cell migration and invasion[78].
miR-330: miR­330 level was higher in HCC tissues if 
compared to adjacent non­neoplastic specimens. The 
up­regulation of miR­330 was associated with shorter 
survival in HCC patients. ING genes have been reported 
to be implicated in apoptosis, cell cycle regulation, 
and DNA repair. ING4 plays important roles in many 
cancer­related processes, such as apoptosis, cell 
proliferation and growth, angiogenesis and migration. 
ING4 expression is decreased in several cancers[81]. 
Overexpression of miR­330 reduced the expression of 
ING4 in HCC cells promoting HCC cell proliferation and 
invasion[82].
MAPK cascade 
The mitogen­activated protein kinase (MAPK) pathway 
is characterized by different kinase proteins that link 
extracellular signals to the machinery that controls 
physiological cellular processes such as growth, 
differentiation, proliferation, migration and apoptosis. 
Alterations in the MAPK cascade impinge on almost 
all previously listed physiological processes and play 
a critical role in the development and progression of 
cancer[83] (Figure 3).
miR-346: miR­346 was down­regulated in HCC tissues 
and its expression levels are associated with tumor size 
and TNM stage. An in vitro study revealed that the loss 
of miR­346 leads to the up­regulation of S phase in 
HCC cell lines. One of the putative targets of miR­346 is 
SMYD3. SMYD3 is an oncogene up­regulated in several 
tumors, including HCC[84]. SMYD3 expression leads 






















Figure 2  JAK/STAT pathway. MicroRNAs deregulated in hepatocellular carcinoma and involved in JSK/STAT pathway.
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signaling and promoting the formation of Ras­driven 
carcinomas[85]. Restoring miR­346 levels in HCC cell 
lines prevented proliferation through the suppression of 
SMYD3 expression[86].
miR-143: miR­143 expression was reduced in 
HCC tumor tissues and human liver cancer cell 
lines (SMMC­7721, Hep3B, HepG2, Huh7, Bel7402, 
MHCC97­H and SK­Hep1) compared to non­neoplastic 
adjacent tissues and normal liver cell line (L02), 
respectively[87]. GATA­binding factor 6 (GATA6) is a 
transcriptional factor with an oncogenic role in various 
types of tumor, favoring cancer progression[88]. GATA6 
is a potential target for miR­143 and its expression is 
downregulated by miR­143 overexpression in HepG2 and 
Bel7402 cells[87].
miR-125a: miR­125a was detected as down­regulated 
in 80% of HCC biopsies if compared with the adjacent 
non­tumor liver tissue. When grouping patients according 
to HCC etiology, miR­125a was downregulated in 80% of 
HBV patients, 78% of HCV patients, and in all 4 patients 
with non­alcoholic steatohepatitis. In vitro analysis 
revealed that MMP11, SIRT7 and c­Raf were the main 
miR­125a targets. In support of this, MMP11, SIRT7 and 
c­Raf were up­regulated in about 80% patients with miR­
125a down­regulation, hinting at an oncosuppressor 
effect of the microRNA through the regulation of MMP11, 
c­Raf and SIRT7 expression[89].
miR-217: miR­217 expression levels in HCC tissues 
were significantly decreased, while MTDH levels were 
significantly upregulated. miR-217 up-regulation in HCC 
cell lines lead to a remarkable downregulation of MTDH 
mRNA expression, demonstrating that MTDH is a target 
of miR­217. Metadherin (MTDH) is a transmembrane 
protein overexpressed in several cancers[90] and it is 
associated with tumor development and with aggressive 
course[49]. In cell lines with miR­217 up­regulation 
and MTDH down­regulation, cell apoptosis notably 
increased, indicating that miRNA expression promotes 
apoptosis of HCC cells[91].
miR-200a: miR­200a was down­regulated in HCC 
cell lines and tissues and it was correlated with the 
metastatic ability of HCC[92]. GAB1 is one of the 
molecules targeted by miR­200a. The overexpression 





















Figure 3  MAPK cascade. MicroRNAs deregulated in hepatocellular carcinoma and involved in MAPK cascade.
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lines, inhibiting cell migration and invasion[92].
TIssUE miRNA AND POsT-sURGICAL 
OUTCOmE 
Liver resection
In a wide­array miRNA analysis on resected patients 
with low­stage HCC (within the Milan criteria), Sato 
et al[93] found that the deregulation of 13 intratumoral 
miRNAs (miR­100, miR­99a, miR­99b, miR­125b, 
miR­378, miR­129­5p, , miR­125a­5p, miR­497, 
miR­22, miR­140­3p, miR­145, miR­221, miR­195) 
significantly correlated with post-surgical (Table 1). The 
same is applies to the deregulation of more than 50 
miRNAs in the non­tumoral tissue, among which the 
most significant was miR-96. miR-125b downregulation, 
in combination with more typical prognostic factors, 
was also correlated with low disease­free survival (DFS) 
after resection in later works[94] (Table 1).
In a more recent study on resected HCC, Lin et al[3] 
identified 16 miRNAs related to MVI, the hierarchical 
clustering of which was able to predict survival after 
resection: miR­452­5p, miR­378, miR­9­5p, miR­550a­
5p, miR­15a­5p, miR­140­5p, let7g, miR­152­3p, miR­
122­5p, miR­212­3p, miR­23b, miR­365a, miR­629­5p, 
miR­1270, miR­659­3p and miR­3941 (Table 1).
Other miRNAs whose down­regulation was correlated 
with poor prognosis after resection were miR342­3p[95], 
miR­655­3p[96], miR­105­1 via NCOA1 deregulation[97], 
miR­223 associated with an increased Stathmin­1 
expression[98], and miR­483­3p in “histologically 
advanced” HCC (high-grade and/or MVI)[99]. Upregulation 
of miR­19b was correlated with good prognosis after 
resection in resected patients with advanced HCC[100]. 
Albeit miRNA down­regulation is often associated to 
worse prognosis, up­regulation is not always a good 
prognostic sign: for example, the up­regulation of 
miR­135a, miR­29a5p and miR­221 was significantly 
associated with early HCC recurrence[101­103] (Table 1).
Liver transplantation
The search for molecular predictors for HCC recurrence 
after orthotopic liver transplantation (OLT) is even 
more tangled than after resection, due to the particular 
immune status of the recipients and the intrinsic 
capability of HCC tumor cells not only to give metastases 
to distant organs, but also to implant in the graft. A wide 
microarray profiling by Barry et al[104] found more than 
60 miRNAs to be deregulated in recurrent HCC after 
OLT. Interestingly, miR­125b and miR­497 ­ already 
mentioned above in post­resection recurrence ­ are 
among the most significant[93,104]. Common mechanisms 
beyond HCC recurrence after both resection and 
liver transplantation are likely to indicate that a more 
aggressive tumor biology leads to a higher risk of 
recurrence or dissemination. 
Morita et al[105] demonstrated that the concomitant 
upregulation of miR­18a and down­regulation of miR­
199a­5p correlated with the worst disease­free survival 
in a population of 70 transplanted patients. The most 
represented sites of recurrence were lymph nodes, lung 
and bone. The mechanisms proposed by the authors 
included the link between miR-18a and TNFα, as well as 
the regulation of the HIF1α, the VEGF-A, and the IGF 
pathways by miR­199a­5p[105] (Table 1).
Response to chemotherapy
The role of miRNAs in the response to chemotherapy is 
still largely unresolved, especially for HCCs, which are 
malignancies with an extreme molecular heterogeneity. 
Due to this heterogeneity, no target therapies specific 
for HCC have been available since the introduction 
of Sorafenib in 2005. Sorafenib changed the natural 
history of patients with advanced HCC not suitable for 
surgery[7], but no molecular markers for the prediction 
of the response to this therapy are available yet. Only 
few in vitro studies focusing on the role of miRNAs 
in the response to Sorafenib exist, e.g., miR­137[106] 
and miR­125a­5p[107]. A very interesting recent study 
Table 1  List of the microRNAs involved in at least one of the main molecular pathways, and with a clinical significance, according 
to the present review
miRNAs (regulation) Pathway Clinical
99a mTOR Recurrence after resection
497 Recurrence after resection, recurrence after transplantation
195 Recurrence after resection
140-5p Recurrence after resection
23b Recurrence after resection
223 Recurrence after resection
199a-5p Recurrence after transplantation
181a-5p Resistance to Sorafenib/CHT
33a-5p Resistance to Sorafenib/CHT
125b Wnt Recurrence after resection, recurrence after transplantation
195 Recurrence after resection
18 (up) Recurrence after transplantation
140-5p JAK-STAT Recurrence after resection
365 Apoptosis Recurrence after resection
125a MAPK Recurrence after resection, resistance to Sorafenib/CHT 
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found that the deregulation of miR­181a­5p in patients’ 
serum was correlated with a worst disease control after 
Sorafenib therapy[108] (Table 1).
As for the resistance to classic chemotherapic 
drugs, other in vitro studies showed that miR­205­
5p and miR­503 were involved in the resistance to 
5­Fuorouracil[109,110], miR­33a­5p was involved in the 
resistance to Cisplatin[111], and miR­31 was involved 
in the resistance to Adriamycin[112]. An exhaustive in 
vitro and in vivo study by Jin et al[113] showed that the 
tissue levels of miR-26a/b regulated the mechanism of 
autophagy, thus influencing the cell’s resistance to drugs. 
So, in spite of the many contributions in the literature 
about miRNAs and HCC, there is a lack of in vivo studies 
on the issue of the response to systemic therapy.
sERUm mIRNAs
The analysis of miRNAs in serum and other body fluids 
(i.e., urines) would be crucial for clinical management, 
since it would allow diagnosis and/or prognosis of HCC 
patients before surgery. However, the study of serum 
miRNAs is still a complicated issue, due to the high 
tumor/patient variability and the lack of a standard 
control among laboratories. miR­122 ­ the miRNA most 
represented quantitatively in the human liver ­ is the 
most promising in early HCC diagnosis, albeit all authors 
generally agree that miR­122 serum levels also increase 
in non­neoplastic liver diseases[114]. The first proposed 
serum panel for HCC detection was miR­122 associated 
with miR­21 and miR­223[115]. A recent meta­analysis 
by Ding et al[116] showed that difficulties exist also in 
the comparison of scientific results among centers: 
the “high­frequency expression miRNAs” best suited 
for HCC diagnosis from serum were miR­122, miR­21, 
and miR­199, and generally a panel of multiple serum 
miRNAs is advisable. For example, a panel composed 
by three serum miRNAs (miR­92­3p, miR­3126­5p and 
miR­107) together with serum alpha­fetoprotein (AFP) 
showed higher sensitivity and specificity in the early 
diagnosis of HCC compared to AFP alone[117]. Another 
study found that serum miR­939, miR­595, miR­519d, 
and miR­494 were able to differentiate cirrhotic patients 
with and without HCC better than AFP[118]. Other serum 
miRNAs are likely to be useful in the diagnosis of local 
or distant HCC recurrence after surgery, like miR­486­
5p[119] and miR­34a[120].
CONCLUsION
The extreme heterogeneity of HCC, in both its 
morphological picture (as assessed by radiologists and 
pathologists) and in its clinical course and outcome, 
reflects the heterogeneity of its bio­molecular 
status. Several molecular pathways are involved in 
hepatocarcinogenesis, as well as in the regenerative­
dysplastic­neoplastic progression observed in cirrhotic 
nodules. As a consequence, the up­ or down­regulation 
of several miRNAs is involved. As evidenced by the 
present review, the most represented miRNA­regulated 
pathway in HCC is mTOR, but other pathways, such 
as as apoptosis, Wnt or MAPK, are also influenced by 
miRNA expression levels. Moreover, as shown in Table 
1, some miRNAs involved in at least one of the main 
molecular pathways of hepatocarcinogenesis are likely 
to have a clinical significance (recurrence after surgery, 
response to systemic therapy).
The identification of specific tissue and serum 
miRNAs, able to predict the arising of HCC in cirrhosis, 
to predict HCC recurrence after surgery, or to predict the 
response to systemic therapy, might lead to a drastic 
improvement in the management of these patients. 
Anyhow, the clinical application of miRNAs has always 
been complicated, especially because of inter­laboratory 
variability, due to the choice of control to be used for 
normalization. A recent study of our group showed 
how the miRNA profile of HCCs changed using a pool of 
cirrhotic tissues or a pool of healthy livers as non­tumor 
controls[121]. Other authors suggested to employ stable 
miRNAs as controls for the study of the expression of 
other miRNAs[122]. In the light of the available data, 
it would be useful to elaborate, based on the most 
representative miRNA in in vivo model (e.g., rat, 
mouse), to better understand the possible role of these 
molecules as theragnostic markers in HCC. The issue 
is still open, and the standardization of miRNA analysis 
among laboratories is crucial for the development of a 
miRNA­based diagnosis of liver nodules, as well as of a 
miRNA­regulatory therapy.
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